This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Thursday's Health Winners & Losers

Earnings were good to a few health companies, such as Immucor (BLUD), but not as nice to others on a gloomy Thursday in the market.

Immucor reported net income of $18.2 million, up 51% from $12.1 million for the same quarter last year. The company said it earned 26 cents a share. The Thomson Financial consensus target was 22 cents a share. The company gained $2.05, or 7.2%, to $30.63.

Also up, Affymetrix (AFFX - Get Report) reported earnings after market close on Wednesday. The company said revenue rose 10% to $88.3 million, and it reported net income of $1.2 million, or 2 cents a share, compared with a loss of $10.1 million, or 15 cents a share, during the same period in 2006.

Looking ahead, Affymetrix is predicting revenue from $365 million to $385 million for fiscal 2007, and gross margins around 60%. Shares climbed $1.44, or 5.8%, to $26.30.

But on the down side, Bristol-Myers Squibb (BMY - Get Report) earned 37 cents a share, excluding one-time items, which is one penny better than the consensus of analysts polled by Thomson First Call. Revenue of $4.93 billion matched expectations. The company raised guidance for the year, but investors seemed dissatisfied -- shares fell $1.33, or 4.2%, to $30.25.

Bristol-Myers Squibb and AstraZeneca are both components of the Amex Pharmaceutical index, which was down 9.42, or 2.8%, to 340.44.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AFFX $12.83 0.94%
BMY $65.89 0.97%
AZN $70.01 -0.09%
MATR $6.33 -0.31%
AAPL $125.83 2.10%

Markets

DOW 17,994.46 +281.80 1.59%
S&P 500 2,087.54 +26.52 1.29%
NASDAQ 4,945.7690 +54.55 1.12%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs